Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis

Abstract

Background:

Autoimmune diseases (ADs) are characterized by immune-mediated tissue damage, in which angiogenesis is a prominent pathogenic mechanism. Vascular endothelial growth factor (VEGF), an angiogenesis modulator, is significantly elevated in several ADs including rheumatoid arthritis (RA), systemic sclerosis (SSc), and systemic lupus erythematosus (SLE). We determined whether circulating VEGF levels were associated with ADs based on pooled evidence.

Methods:

The analyses included 165 studies from the PubMed, EMBASE, Cochrane Library, and Web of Science databases and fulfilled the study criteria. Comparisons of circulating VEGF levels between patients with ADs and healthy controls were performed by determining pooled standard mean differences (SMDs) with 95% confidence intervals (CIs) in a random-effect model using STATA 16.0. Subgroup, sensitivity, and meta-regression analyses were performed to determine heterogeneity and to test robustness.

Results:

Compared with healthy subjects, circulating VEGF levels were significantly higher in patients with SLE (SMD 0.84, 95% CI 0.25–1.44, P = 0.0056), RA (SMD 1.48, 95% CI 0.82–2.15, P <0.0001), SSc (SMD 0.56, 95% CI 0.36–0.75, P <0.0001), Behcet’s disease (SMD 1.65, 95% CI 0.88–2.41, P <0.0001), Kawasaki disease (SMD 2.41, 95% CI 0.10–4.72, P = 0.0406), ankylosing spondylitis (SMD 0.78, 95% CI 0.23–1.33, P = 0.0052), inflammatory bowel disease (SMD 0.57, 95% CI 0.43–0.71, P <0.0001), psoriasis (SMD 0.98, 95% CI 0.62–1.34, P <0.0001), and Graves’ disease (SMD 0.69, 95% CI 0.20–1.19, P = 0.0056). Circulating VEGF levels correlated with disease activity and hematological parameters in ADs.

Conclusion:

Circulating VEGF levels were associated with ADs and could predict disease manifestations, severity and activity in patients with ADs.

Systematic Review Registration:

PROSPERO, identifier CRD42021227843.

Introduction

Angiogenesis, a hallmark of inflammatory activation, is an integral part of pathogenic processes including endothelial cell proliferation and migration and subsequent neoangiogenesis and remodeling in autoimmune diseases (ADs). Synovial pannus initiates the invasion of cartilage and subchondral bone to perpetuate rheumatoid arthritis (RA) (1, 2), whereas ankylosing spondylitis (AS) is characterized by increased vascularity and vascular lesions (3). Vascular endothelial dysfunction and injury are considered as the primum movens triggering Kawasaki disease (KD), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), Behcet’s disease (BD), systemic sclerosis (SSc), and psoriasis (PsA) (4–9). Therefore, early detection of vascular involvement is pivotal in AD diagnosis.

Vascular endothelial growth factor (VEGF)-A, generally known as VEGF, is a crucial regulator of endothelial dysfunction, capillary permeability, and angiogenesis. For example, serum VEGF level and intrathyroid microvessel density were reported to be increased patients with Graves’ disease (GD) compared to healthy control (HC) subjects (10). Increased serum VEGF and significant difference in diffused and limited SSc suggest VEGF as a potential surrogate indicator of capillary damage (11). Strong VEGF expression in synovial fluid and serum of patients with RA was shown to lead to synovial neovascularization and destruction in cartilage and bones (12, 13). VEGF was reported to be overexpressed in the skin and peripheral blood of patients with PsA (14). Serum VEGF levels were shown to be elevated and to correlate with disease activity and severity in PsA, SLE, BD, IBD, KD, and AS (14–19). These findings suggest VEGF as a potential pathogenic factor with promising diagnostic value in ADs. However, no clinical guidelines currently recommend serum VEGF evaluation in routine care and counseling of patients with ADs, and intensive studies are warranted to identify the clinical implications of the findings regarding VEGF’s role in ADs to date and to resolve contradictory results (20–24).

Given the inconsistency among these findings and lower statistic power of the studies, we performed a systematic review and meta-analysis to generate independent results and recognize the source of heterogeneity. In the present study, we aimed to determine whether circulating VEGF was a causative factor in ADs.

Materials and Methods

Literature Search

The present systematic review with meta-analysis was performed according to the PRISMA guidelines (PROSPERO registration number, CRD42021227843). Two authors (HTZ and HLL) independently searched the PubMed, Embase, Cochrane Library, and the Web of Science databases for studies published until October 14. The detailed search strategies are provided in the online Supplemental Materials. Reference lists were manually retrieved.

Eligibility Criteria

Without restrictions on time, language, ethnicity, and geographical region, studies satisfying the following criteria were included: (1) case-control or cohort studies on the association between circulating VEGF and ADs including SLE, RA, SSc, BD, KD, AS, IBD, PsA, and GD; (2) HCs without ADs (2); available data on circulating VEGF levels (serum or plasma); (3) sufficient data on VEGF levels for both HCs and patients with ADs to evaluate standard mean differences (SMDs) with 95% confidence intervals (CIs). Studies based on animal and cellular models, those comprising HCs with insufficient data; and editorial letters with insufficient data were excluded.

Data Extraction and Quality Assessment

Two independent investigators (HTZ and HLL) individually screened the literature and extracted and evaluated the data. Any discrepancies were resolved by consensus or by a third opinion (YZL). Study number, name of the first author, publication year, country, study type, sample type, inclusion and exclusion criteria, demographic features, aggregated number of subjects and circulating VEGF levels in patients with ADs and HCs, diagnostic criteria, type of VEGF assay, and treatment history and strategy were extracted into pre-designed charts. For meta-analysis, continuous variables were translated from medians (interquartile range [IQR] or range) to means ± standard deviation (25). Newcastle–Ottawa quality assessment scale was used to evaluate study quality. Further details of the pooled studies were obtained by directly contacting the authors if warranted.

Data Analysis

STATA V.16.0 was used to perform the meta-analysis. SMDs with 95% CIs were used to estimate the pooled results and compare circulating VEGF levels between patients and HC groups. Random-effect model was used for analysis. Significant heterogeneity was ascertained based on a p value of ≤0.10 using the Cochrane Q test or an I² value of >50%. Subgroup, sensitivity, and meta-regression analyses were performed to identify the source of heterogeneity and to test robustness. Spearman correlation coefficients were transformed into Pearson’s r values, which were converted to Fisher’s z values to obtain approximately normal distributions. Ultimately, the summary Fisher’s z values were converted into summary r values. Summary r values of 0.8–1.0, 0.6–0.8, 0.4–0.6, and 0.2–0.4 indicated extreme, high, and moderate relevance and poor correlation, respectively (details provided in the online Supplemental Materials). Publication bias was assessed by Egger’s linear regression test and contour-enhanced funnel plots with collaborative meta-trim. A two-sided P <0.05 was considered to indicate statistical significance.

Results

Search Results and Population Characteristics

The literature search is summarized in Figure 1. After removing duplicate studies (n = 3,322) and irrelevant publications (n = 8,673), 298 articles were analyzed and the full texts of 273 articles were read. Thirty-two full-text articles were eliminated due to incomplete data or unrelated outcomes. Among 241 eligible studies meeting the inclusion criteria, 76 articles were excluded due to unextractable data, insufficient data on HCs, irrelevant VEGF sample type (urine/synovial fluid/tear fluid), or inappropriate disease control groups. Finally, 165 studies were included in the meta-analysis, with 28, 29, 40, 13, 8, 12, 16, 23, and six studies on SLE (20, 21, 26–51), RA (12, 22–24, 38, 43, 52–74), SSc (11, 38, 39, 64, 75–110), BD (111–123), KD (18, 124–130), AS (55, 73, 131–140), IBD (141–156), PsA (12, 14, 135, 136, 157–175) and GD (10, 176–180), respectively. The main study characteristics are summarized in Table 1 and Appendix 1. The studies were medium-to-high quality based on the Newcastle–Ottawa quality assessment scale scores (range, 4–9).

Figure 1

Meta-Analysis of the Association Between Circulating VEGF and SLE

Circulating VEGF levels were significantly higher in SLE than in HC (SMD 0.84, 95%CI 0.25–1.44, P = 0.0056) (Figure 2A). Additionally, circulating VEGF was higher in active SLE than in inactive SLE (SMD 0.80, 95%CI 0.02–1.59, P = 0.0454) (Figure 2B-i), serum VEGF levels remained remarkable higher in active SLE than in inactive SLE (SMD 0.51, 95% CI 0.33–0.70, P <0.0001) (Figure 2B-ii), whereas serum VEGF levels were significantly higher in SLE with renal involvement than that without renal involvement (SMD 1.43, 95% CI 0.58–2.28, P = 0.0010) (Figure 2C). Due to the observed heterogeneity, the sample types were stratified (serum versus plasma); the heterogeneity in serum VEGF levels in active and inactive SLE disappeared after removing studies using plasma (before, I² = 94.04%, P = 0.0002; after, I² = 0.00%, P = 0.3178).

Figure 2

The subgroup analysis indicated significantly higher serum (SMD 0.64, 95% CI 0.37–0.91, P <0.0001) and plasma (SMD 1.56, 95% CI 0.49–2.63, P = 0.0040) VEGF levels in SLE (Figure 2D-i). Significantly higher circulating VEGF levels were present in small (n ≤50) (SMD 0.96, 95% CI 0.56–1.35, P <0.0001) and large (n >50) (SMD 0.39, 95% CI 0.07–0.72, P = 0.0170) studies (Figure 2D-ii).

Meta-regression analysis adjusted for age and percentage of female patients demonstrated age (P = 0.0030) but not sex (P = 0.9700) had a significant effect.

Meta-Analysis of the Association Between Circulating VEGF and RA

Circulating VEGF levels were significantly higher in RA than in HC (SMD 1.48, 95% CI 0.82–2.15, P <0.0001) (Figure 3A). Overall heterogeneity was apparent.

Figure 3

The subgroup analysis indicated significantly higher VEGF levels in serum (SMD 1.49, 95% CI 1.09–1.88, P <0.0001) but not plasma (P = 0.0820) in RA (Figure 3B-i). Higher circulating VEGF levels were present in small (n ≤50) (SMD 1.58, 95% CI 1.10–2.05, P <0.0001) and large (n >50) (SMD 1.03, 95% CI 0.47–1.60, P <0.0001) studies on RA (Figure 3B-ii).

Meta-regression analysis adjusted for age and female sex demonstrated neither age (P = 0.4090) nor sex (P = 0.7570) had a significant effect.

Meta-Analysis of the Association Between Circulating VEGF and SSc

Circulating VEGF levels were significantly higher in SSc than in HC (SMD 0.56, 95% CI 0.36–0.75, P <0.0001) (Figure 4A). The comparison of serum VEGF levels between limited and diffused SSc did not reach statistical significance (P = 0.2735) (Figure 4B).

Figure 4

The subgroup analysis performed due to the obvious overall heterogeneity (I² = 98.35%, P <0.0001) revealed significantly higher VEGF levels in serum (SMD 0.48, 95% CI 0.28–0.67, P <0.0001) and plasma (SMD 0.86, 95% CI 0.49–1.24, P <0.0001) samples of patients with SSc (Figure 4C-i). Elevated circulating VEGF levels were observed in small (n ≤50) (SMD 0.57, 995% CI 0.33–0.81, P <0.0001) and large (n >50) (SMD 0.52, 95% CI 0.28–0.75, P <0.0001) studies on SSc (Figure 4C-ii).

Meta-regression analysis adjusted for age and female sex demonstrated neither age (P = 0.2740) nor sex (P = 0.7020) had a significant effect.

Meta-Analysis of the Association Between Circulating VEGF and BD

Circulating VEGF levels were significantly higher in BD than in HC (SMD 1.65, 95% CI 0.88–2.41, P <0.0001) (Figure 5A) as well as in active BD than in inactive BD (SMD 0.91, 95% CI 0.26–1.55, P = 0.0064) (Figure 5B). Heterogeneity was present.

Figure 5

The subgroup analysis revealed significantly elevated serum VEGF levels (SMD 1.60, 95% CI 0.85–2.34, P <0.0001) (Figure 5C-i), specifically in small (n ≤50) (SMD 1.86, 95% CI 1.15–2.57, P <0.0001) and not in large (n >50) studies (P = 0.1200) (Figure 5C-ii).

Meta-regression analysis adjusted for age and female sex demonstrated neither age (P = 0.2700) nor sex (P = 0.0720) had a significant effect.

Meta-Analysis of the Association Between Circulating VEGF and KD

Circulating VEGF levels were elevated in KD than in HC (SMD 2.41, 95% CI 0.10–4.72, P = 0.0406) (Figure S1A) and febrile controls (SMD 1.08, 95% CI 0.02–2.14, P = 0.0452) (Figure S1B). The comparison of serum VEGF levels between acute and convalescent KD revealed no statistical significance (P = 0.0831) (Figure S1C). Heterogeneity was prominent.

The subgroup analysis indicated serum VEGF levels were higher in KD than in HC (SMD 2.26, 95% CI 0.93–3.58, P = 0.0010) (Figure S1D-i). Increased circulating VEGF levels were found in small (n ≤50) (SMD 1.36, 95% CI 0.45–2.27, P = 0.0030) and large (n >50) studies (SMD 3.19, 95% CI 1.01–5.38, P = 0.0040) (Figure S1D-ii). Meta-regression analysis adjusted for age and female sex demonstrated female sex (P = 0.0100) but not age (P = 0.1280) had a significant effect.

Meta-Analysis of the Association Between Circulating VEGF and AS

Circulating VEGF levels were significantly elevated in AS than in HC (SMD 0.78, 95% CI 0.23–1.33, P = 0.0052) (Figure S2A). The overall heterogeneity was apparent (I² = 95.68%, P <0.0001).

The subgroup analysis revealed significantly higher serum VEGF levels in AS than in HC (SMD 0.60, 95% CI 0.36–0.84, P <0.0001) (Figure S2B-i). Significantly elevated circulating VEGF levels were found in small (n ≤50) (SMD 1.66, 95% CI 0.35–2.98, P = 0.0130) and large (n >50) studies (SMD 0.55, 95% CI 0.29–0.80, P <0.0001) on AS (Figure S2B-ii).

Meta-regression analysis adjusted for age and female sex demonstrated neither age (P = 0.8040) nor sex (P = 0.8500) had a significant effect.

Meta-Analysis of the Association Between Circulating VEGF and IBD

Serum VEGF levels were significantly higher in IBD than in HC (SMD 0.57, 95% CI 0.43–0.71, P <0.0001) (Figure S3A). The overall heterogeneity was extremely low (I² = 3.12%, P <0.0001). Meta-regression analysis adjusted for age or females demonstrated insignificant effect of age (P = 0.0760) and sex (P = 0.2610).

Serum VEGF levels were significantly higher in ulcerative colitis (UC) than in HC (SMD 0.69, 95% CI 0.21–1.16, P = 0.0048) (Figure S3B-i). Both the studies on active UC and those that did not specify disease activity reported significantly higher serum VEGF levels in UC (SMD 0.75, 95% CI 0.17–1.34, P = 0.0120 and SMD 0.56, 95% CI 0.20–0.93, P = 0.0030, respectively) (Figure S3D-i). The serum VEGF levels were not significantly different between active and inactive UC (P = 0.1658) (Figure S3C-i). Meta-regression analysis adjusted for age and female sex demonstrated insignificant effects of age (P = 0.8330) and sex (P = 0.2150).

Serum VEGF levels were significantly higher in Crohn’s disease (CD) than in HC (SMD 0.72, 95% CI 0.29–1.16, P = 0.0011) (Figure S3B-ii). Both the studies on active CD and those that did not specify disease activity reported significantly higher serum VEGF levels in CD (SMD 0.62, 95% CI 0.10–1.15, P = 0.0200 and SMD 0.78, 95% CI 0.33–1.22, P = 0.0010, respectively) (Figure S3D-ii). Significantly increased serum VEGF levels were present in small (n ≤50) (SMD 0.86, 95% CI 0.32–1.40, P = 0.002) but not in large (n >50) studies (P = 0.0600) (Figure S3D-iii). Moreover, serum VEGF levels were significantly higher in active CD than in inactive CD (SMD 0.53, 95% CI 0.09–0.96, P = 0.0176) (Figure S3C-ii). Meta-regression analysis adjusted for age and female sex demonstrated age (P = 0.0120) and sex (P = 0.0010) had significant effects.

Meta-Analysis of the Association Between Circulating VEGF and PsA

Circulating VEGF levels were significantly higher in PsA (SMD 0.98, 95% CI 0.62–1.34, P <0.0001) (Figure S4A), in psoriatic arthritis (SMD 0.72, 95% CI 0.12–1.32, P = 0.0192) (Figure S4B), and psoriasis with skin involvement (SMD 1.26, 95% CI 0.65–1.86, P = 0.0001) than in HC (Figure S4C). Heterogeneity was observed in the analyses.

The subgroup analysis indicated significantly higher serum (SMD 1.02, 95% CI 0.50–1.55, P <0.0001) and plasma (SMD 0.67, 95% CI 0.37–0.97, P <0.0001) VEGF levels in PsA (Figure S4D-i). Significantly higher circulating VEGF levels were found in small (n ≤50) (SMD 0.80, 95% CI 0.49–1.11, P <0.0001) and large (n >50) (SMD 1.12, 95% CI 0.40–1.83, P = 0.0020) studies on PsA (Figure S4D-ii). Meta-regression analysis adjusted for age and female sex demonstrated that neither age (P = 0.0570) nor sex (P = 0.1890) had a significant effect.

Meta-Analysis of the Association Between Circulating VEGF and GD

Circulating VEGF levels were significantly higher in GD than in HC (SMD 0.69, 95% CI 0.20–1.19, P = 0.0056), with considerable heterogeneity (Figure S5A). Circulating VEGF levels were higher in active than in inactive Graves’ ophthalmopathy (GO) (SMD 0.80, 95% CI 0.29–1.30, P = 0.0019), without any heterogeneity (I² = 0.00%, P = 0.7548) (Figure S5B).

Serum (SMD 0.77, 95% CI 0.27–1.28, P = 0.0020) but not plasma (P = 0.3880) VEGF levels were significantly higher in GD than in HC (Figure S5C). Meta-regression analysis adjusted for age and female sex demonstrated the significant effect of age (P = 0.0070) but not sex (P = 0.2420).

Correlation Analyses Between Circulation VEGF and AD Clinical Features

We explored the potential correlation of VEGF in clinical implications and hematological indicators of ADs. For SLE (Figure S6), the summary Fisher’s z showed a positive, moderate correlation between circulating VEGF level and disease activity (SLEDAI/SLAM, ES 0.55, 95% CI 0.29–0.81, P <0.0001; summary r = 0.50), erythrocyte sedimentation rate (ESR; ES 0.40, 95% CI 0.18–0.63, P = 0.0004; summary r = 0.38). A negative, poor correlation was found for C3 (ES −0.45, 95% CI −0.81 to −0.08, P = 0.0162, summary r = −0.42). There was no correlation between circulating VEGF level and platelet count (P = 0.1163).

In RA (Figure S7), there was a positive, weak correlation between circulating VEGF and disease activity (DAS-28; ES 0.33, 95% CI 0.22–0.44, P <0.0001, summary r = 0.32), ESR (ES 0.35, 95% CI 0.18–0.51, P <0.0001; summary r = 0.34) as well as C-reactive protein (CRP; ES 0.38, 95% CI 0.24–0.52, P <0.0001; summary r = 0.36).

In SSc (Figure S8), there was a positive, moderate relationship between circulating VEGF level and pulmonary artery pressure (ES 0.62, 95% CI 0.37–0.87, P <0.0001; summary r = 0.55) and Medical Research Council dyspnea score (ES 0.65, 95% CI 0.08–1.22, P = 0.0246; summary r = 0.57). There was no relationship between circulating VEGF level and modified Ronan skin score (P = 0.3100).

In BD (Figure S9), summary correlation coefficients indicated a significant, positive, and strong correlation with disease activity based on Behcet’s disease current activity form score (ES 1.22, 95% CI 0.03–2.41, P = 0.0446, summary r = 0.84) and moderate correlation with ESR (ES 0.47, 95% CI 0.11–0.82, P = 0.0108, summary r = 0.44).

In AS (Figure S10), circulating VEGF level was poorly correlated with disease activity (BASDAI/BASMI; ES 0.35, 95% CI 0.09–0.60, P = 0.0080; summary r = 0.34), ESR (ES 0.26, 95% CI 0.17–0.36, P <0.0001; summary r = 0.25), and CRP (ES 0.24, 95% CI 0.14–0.35, P <0.0001; summary r = 0.24).

In IBD (Figure S11), circulating VEGF level exhibited a positive, poor correlation with Crohn’s disease activity index (CDAI; ES 0.34, 95% CI 0.10–0.57, P = 0.0053, summary r = 0.33), medium correlation with UC activity index (UDAI; ES 0.57, 95% CI 0.29–0.86, P = 0.0001; summary r = 0.52), strong correlation with ESR (ES 0.87, 95% CI 0.63–1.12, P <0.0001; summary r = 0.70), and weak correlation with platelet count (ES 0.32, 95% CI 0.16–0.49, P = 0.0001; summary r 0.31).

In PsA (Figure S12), circulating VEGF level was positively correlated with psoriasis area and severity index score (ES 1.12, 95% CI 0.64–1.60, P <0.0001; summary r = 0.81) and had a positive, moderate correlation with disease duration (ES 0.51, 95% CI 0.32–0.69, P <0.0001; summary r = 0.47).

Sensitivity Analysis and Publication Bias

The sensitivity analysis revealed the stability of pooled results (data not shown). For SLE, RA, SSc, KD, and AS, the contour-enhanced funnel plots revealed no publication bias (Figure S13), the meta-trim practice demonstrated that all imputed studies fell into the significant region. In contrast, Egger’s test suggested publication bias for SLE, RA, and KD (P <0.0001 for all) as well as for AS (P = 0.0001). However, there was consistency in publication bias for SSc by Egger’s test (P = 0.1413). This remind us to be cautious with using Egger’s test to determine publication bias in small number of studies (<20). There was no publication bias with PsA and GD (P = 0.4874 and P = 0.5419, respectively), in contrast to that observed with BD (P = 0.0006). The imputed studies on IBD fell into the non-significant region, and Egger’s test also represented evidence of it (P = 0.0017) in UC; the existence of publication bias was proven by Egger’s test (P = 0.0113) in CD.

Discussion

In the current meta-analysis, we found a close relationship between circulating VEGF level and ADs. First, our analyses revealed significantly increased circulating VEGF levels in SLE, RA, SSc, BD, KD, AS, IBD, PsA, and GD. Additionally, we showed that serum VEGF could distinguish active from inactive SLE and renal from non-renal SLE; it could also discriminate between active and inactive CD. Likewise, circulating VEGF had a strong ability to differentiate active from inactive BD and GO. Serum VEGF exhibited its dipartite boundedness in limited/diffused cutaneous SSc, active/inactive UC, and acute/convalescent KD. Furthermore, we demonstrated the correlation of circulating VEGF levels with metrics of disease activity and severity (SLEDAI/SLAM, DAS-28, MRC dyspnea score, modified Ronan skin score, BD current activity form score, BASDAI/BASMI, CDAI, UDAI, psoriasis area and severity index) as well as with hematological parameters (ESR, CRP, platelet count, pulmonary artery pressure). Overall, these results indicate that circulating VEGF reflects pathogenesis and should be considered as a potent hematological marker for diagnosis and disease progression in ADs.

Structural and functional abnormities in neovasculature may lead to damage in chronic inflammatory diseases. Consecutive angiogenesis and immune-mediated vascular endothelial cell injury and dysfunction as well as persistent inflammation play important pathological roles in SLE (20), whereas expansion and invasion of synovial vessels facilitate inflammation and erosive joint destruction in RA (12). Early generalized microvascular endothelial damage leading to immune activation and defective angiogenesis are significant events in cumulative systemic fibrosis and microangiopathy in SSc (76). Additionally, BD is characterized by systemic vasculitis, inflammatory infiltrates, subsequent vascular lesions, and neovascularization (113, 115), whereas subendothelial edema and fenestrated endothelium constitute acute systemic vasculitis observed in KD (181). Structural changes in vascular endothelium due to inflammation and hypoxia stimulate angiogenesis to permeate vascular and mediate tissue repair in IBD (6). Finally, early psoriatic skin plaque formation is triggered by inappropriate expansion and vascular alterations, pronounced permeability, and endothelial cell proliferation (162). Therefore, angiogenesis and angiopathy are considered as major pathogenic events predisposing to ADs.

VEGF, an increasingly recognized proangiogenic inducer of endothelial proliferation and microvascular hyperpermeability, may reverse the tide of inducers against inhibitors and promote angiogenesis (182). Despite the unclear role of angiogenesis in AS and GD, higher-than-normal VEGF levels support its role in bone and enchondral ossification in AS (183) and increased microvessel density in GD (184). Over the past decades, numerous studies have reported increased VEGF levels in ADs, beyond its well-known role in tumorigenesis. In the present study, our meta-analysis reveals differences in circulating VEGF levels between patients with ADs and HC subjects, providing further evidence for its utility in determining disease activity and severity in ADs.

In the present meta-analysis, there were variations in circulating VEGF levels due to differences in sample collection methods and demographic characteristics across the studies, requiring adjustment for the interpretation of the final laboratory results. Serum VEGF levels are 7–10 times higher than plasma VEGF levels in RA (60). Serum VEGF is a combination of efflux from platelets, neutrophils during coagulation, and circulating VEGF, which rarely occurs in vivo; in contrast, plasma VEGF directly reflects circulating VEGF in the absence of coagulation in vivo. In support of this difference, the present meta-analysis also revealed that the removal of plasma samples from the analysis led to the disappearance of heterogeneity in serum VEGF levels in active and inactive SLE. Plasma samples with citrate anticoagulants had the lowest VEGF levels, reflecting that that reservation of platelets VEGF releasing is effective and that different anticoagulation procedures should be considered in evaluating variations in VEGF levels across studies. Higher plasma VEGF levels in female patients compared with male patients, increasing VEGF levels with age in adults, and decreasing VEGF levels with age in children illustrate the contributory roles of sex and age to discrepancy (185). The cohort size in specific studies might also impact the mean and standard deviation. Therefore, we addressed these variables in subgroup and meta-regression analyses. The subgroup analyses explored the source of heterogeneity in serum VEGF levels for only studies on active and inactive SLE (before, I² = 94.04%, P = 0.0002; after, I² = 0.00%, P = 0.3178). We also observed apparent associations of circulating VEGF levels with age and female sex in SLE and CD, with sex in KD, and with age in GD.

There are several limitations in the present meta-analysis. First, although subgroup and meta-regression analyses were performed to explore heterogeneity, much of it remains to be explained and reported. Second, the funnel plots indicated publication bias in studies on BD and IBD, including UC as well as CD, which might have led to the overestimation of pooled SMDs. Third, data could not be fully retrieved, which might have resulted in missing values in meta-regression and the omission of covariates in tests assessing heterogeneity. Availability of complete data on patient inclusion and exclusion criteria, ethnicity, AD treatment details, and exact timing and method of VEGF measurement would greatly reduce the bias in our analyses. Although the existing heterogeneity could be partially explained by age, sex, sample type, and sample size of the individual studies, an exact conclusion could not be drawn due to the lacking explanation for the remaining heterogeneity. Further studies using more comprehensive data should be performed to elucidate the association of circulating VEGF levels with ADs.

In conclusion, our meta-analysis unveiled a close association between circulating VEGF levels and ADs including disease activity and severity as well as clinical hematological manifestations. Serum VEGF is a reliable marker that can distinguish active from inactive in SLE and GO and can potentially differentiate IBD from HC. Early and regular measurement of circulating VEGF levels may be considered as a noninvasive method to monitor vascular involvement and activity in ADs. Future studies should focus on the prognostic and diagnostic utility of circulating VEGF, its role in pathogenesis, and the utility of VEGF-targeted therapeutic strategies in ADs.

Funding

This research was supported by grants from the National Natural Science Foundation of China Grants (81871302) and Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project (No. ZK201000).

References

• 1

  KochAE. Angiogenesis as a Target in Rheumatoid Arthritis. Ann Rheum Dis (2003) 62(Suppl 2):ii60–7. doi: 10.1136/ard.62.suppl_2.ii60

  • CrossRef
  • Google Scholar

• 2

  BrenchleyPE. Angiogenesis in Inflammatory Joint Disease: A Target for Therapeutic Intervention. Clin Exp Immunol (2000) 121:426–9. doi: 10.1046/j.1365-2249.2000.01299.x

  • CrossRef
  • Google Scholar

• 3

  KiddBLMooreKWaltersMTSmithJLCawleyMI. Immunohistological Features of Synovitis in Ankylosing Spondylitis: A Comparison With Rheumatoid Arthritis. Ann Rheum Dis (1989) 48:92–8. doi: 10.1136/ard.48.2.92

  • CrossRef
  • Google Scholar

• 4

  TeraiMYasukawaKNarumotoSTatenoSOanaSKohnoY. Vascular Endothelial Growth Factor in Acute Kawasaki Disease. Am J Cardiol (1999) 83:337–9. doi: 10.1016/s0002-9149(98)00864-9

  • CrossRef
  • Google Scholar

• 5

  CiołkiewiczMKuryliszyn-MoskalAKlimiukPA. Analysis of Correlations Between Selected Endothelial Cell Activation Markers, Disease Activity, and Nailfold Capillaroscopy Microvascular Changes in Systemic Lupus Erythematosus Patients. Clin Rheumatol (2010) 29:175–80. doi: 10.1007/s10067-009-1308-7

  • CrossRef
  • Google Scholar

• 6

  CiborDDomagala-RodackaRRodackiTJurczyszynAMachTOwczarekD. Endothelial Dysfunction in Inflammatory Bowel Diseases: Pathogenesis, Assessment and Implications. World J Gastroenterol (2016) 22:1067–77. doi: 10.3748/wjg.v22.i3.1067

  • CrossRef
  • Google Scholar

• 7

  SakaneTTakenoMSuzukiNInabaG. Behçet’s Disease. N Engl J Med (1999) 341:1284–91. doi: 10.1056/nejm199910213411707

  • CrossRef
  • Google Scholar

• 8

  SgoncRGruschwitzMSDietrichHRecheisHGershwinMEWickG. Endothelial Cell Apoptosis is a Primary Pathogenetic Event Underlying Skin Lesions in Avian and Human Scleroderma. J Clin Invest (1996) 98:785–92. doi: 10.1172/jci118851

  • CrossRef
  • Google Scholar

• 9

  HennoABlacherSLambertCADeroanneCNoëlALapièreCet al. Histological and Transcriptional Study of Angiogenesis and Lymphangiogenesis in Uninvolved Skin, Acute Pinpoint Lesions and Established Psoriasis Plaques: An Approach of Vascular Development Chronology in Psoriasis. J Dermatol Sci (2010) 57:162–9. doi: 10.1016/j.jdermsci.2009.12.006

  • CrossRef
  • Google Scholar

• 10

  ChengCWWuCZTangKTFangWFLinJD. Simultaneous Measurement of Twenty-Nine Circulating Cytokines and Growth Factors in Female Patients With Overt Autoimmune Thyroid Diseases. Autoimmunity (2020) 53:261–9. doi: 10.1080/08916934.2020.1755965

  • CrossRef
  • Google Scholar

• 11

  ChoiJJMinDJChoMLMinSYKimSJLeeSSet al. Elevated Vascular Endothelial Growth Factor in Systemic Sclerosis. J Rheumatol (2003) 30(7):1529–33.

  • Google Scholar

• 12

  BallaraSTaylorPCReuschPMarméDFeldmannMMainiRNet al. Raised Serum Vascular Endothelial Growth Factor Levels are Associated With Destructive Change in Inflammatory Arthritis. Arthritis Rheumatol (2001) 44:2055–64. doi: 10.1002/1529-0131(200109)44:9<2055::Aid-art355>3.0.Co;2-2

  • CrossRef
  • Google Scholar

• 13

  FavaRAOlsenNJSpencer-GreenGYeoKTYeoTKBerseBet al. Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue. J Exp Med (1994) 180:341–6. doi: 10.1084/jem.180.1.341

  • CrossRef
  • Google Scholar

• 14

  AblinJNGoldsteinZAloushVMatzHElkayamOCaspiDet al. Normal Levels and Function of Endothelial Progenitor Cells in Patients With Psoriatic Arthritis. Rheumatol Int (2009) 29:257–62. doi: 10.1007/s00296-008-0676-7

  • CrossRef
  • Google Scholar

• 15

  ZhouLLuGShenLWangLWangM. Serum Levels of Three Angiogenic Factors in Systemic Lupus Erythematosus and Their Clinical Significance. BioMed Res Int (2014) 2014:627126. doi: 10.1155/2014/627126

  • CrossRef
  • Google Scholar

• 16

  AricaDAAkşanBÖremAAltinkaynakBAYayliSSönmezM. High Levels of Endothelial Progenitor Cells and Circulating Endothelial Cells in Patients With Behçet’s Disease and Their Relationship to Disease Activity. Bras Dermatol (2019) 94:320–6. doi: 10.1590/abd1806-4841.20198169

  • CrossRef
  • Google Scholar

• 17

  AksoyEKÇetinkayaHSavaşBEnsariATorgutalpMEfeC. Vascular Endothelial Growth Factor, Endostatin Levels and Clinical Features Among Patients With Ulcerative Colitis and Irritable Bowel Syndrome and Among Healthy Controls: A Cross-Sectional Analytical Study. Sao Paulo Med J (2018) 136:543–50. doi: 10.1590/1516-3180.2018.0274161118

  • CrossRef
  • Google Scholar

• 18

  OhnoTIgarashiHInoueKAkazawaKJohoKHaraT. Serum Vascular Endothelial Growth Factor: A New Predictive Indicator for the Occurrence of Coronary Artery Lesions in Kawasaki Disease. Eur J Pediatr (2000) 159:424–9. doi: 10.1007/s004310051300

  • CrossRef
  • Google Scholar

• 19

  LinTTLuJQiCYYuanLLiXLXiaLPet al. Elevated Serum Level of IL-27 and VEGF in Patients With Ankylosing Spondylitis and Associate With Disease Activity. Clin Exp Med (2015) 15:227–31. doi: 10.1007/s10238-014-0281-x

  • CrossRef
  • Google Scholar

• 20

  BarbulescuALVrejuAFBugaAMSanduRECriveanuCTudorascuDRet al. Vascular Endothelial Growth Factor in Systemic Lupus Erythematosus - Correlations With Disease Activity and Nailfold Capillaroscopy Changes. Romanian J Morphol Embryol (2015) 56(3):1011–6.

  • Google Scholar

• 21

  BarracloughMMcKieSParkerBJacksonAPembertonPElliottRet al. Altered Cognitive Function in Systemic Lupus Erythematosus and Associations With Inflammation and Functional and Structural Brain Changes. Ann Rheumatic Dis (2019) 78:934–40. doi: 10.1136/annrheumdis-2018-214677

  • CrossRef
  • Google Scholar

• 22

  FosterWCarruthersDLipGYHBlannAD. Relationships Between Endothelial, Inflammatory and Angiogenesis Markers in Rheumatoid Arthritis: Implications for Cardiovascular Pathophysiology. Thromb Res (2009) 123:659–64. doi: 10.1016/j.thromres.2008.06.014

  • CrossRef
  • Google Scholar

• 23

  MisraSMondalSChatterjeeSGuinASinhamahapatraPGhoshA. Association of Angiogenic and Inflammatory Markers With Power Doppler Ultrasound Vascularity Grade and DAS28-CRP in Early Rheumatoid Arthritis: A Comparative Analysis. BioMed Res Int (2018) 2018:6906374. doi: 10.1155/2018/6906374

  • CrossRef
  • Google Scholar

• 24

  SoneHSakauchiMTakahashiASuzukiHInoueNIidaKet al. Elevated Levels of Vascular Endothelial Growth Factor in the Sera of Patients With Rheumatoid Arthritis Correlation With Disease Activity. Life Sci (2001) 69:1861–9. doi: 10.1016/s0024-3205(01)01264-4

  • CrossRef
  • Google Scholar

• 25

  WanXWangWLiuJTongT. Estimating the Sample Mean and Standard Deviation From the Sample Size, Median, Range and/or Interquartile Range. BMC Med Res Methodol (2014) 14:135. doi: 10.1186/1471-2288-14-135

  • CrossRef
  • Google Scholar

• 26

  CiprandiGMurdacaGColomboBMDe AmiciMMarsegliaGL. Serum Vascular Endothelial Growth Factor in Allergic Rhinitis and Systemic Lupus Erythematosus. Hum Immunol (2008) 69:510–2. doi: 10.1016/j.humimm.2008.05.010

  • CrossRef
  • Google Scholar

• 27

  ColomboBMCacciapagliaFPuntoniMMurdacaGRossiERodriguezGet al. Traditional and non Traditional Risk Factors in Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Role of Vascular Endothelial Growth Factor (VEGATS Study). Autoimmun Rev (2009) 8:309–15. doi: 10.1016/j.autrev.2008.10.002

  • CrossRef
  • Google Scholar

• 28

  De JesusGROliveiraCSDos SantosFCDe JesusNRPortoLCLevyRAet al. Angiogenic and Antiangiogenic Factors in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol (2014) 66:S1157. doi: 10.1002/art.38914

  • CrossRef
  • Google Scholar

• 29

  DingYLiaoWYiZWXiangWHeXJ. Association of miRNA-145 Expression in Vascular Smooth Muscle Cells With Vascular Damages in Patients With Lupus Nephritis. Int J Clin Exp Pathol (2015) 8(10):12646–56.

  • Google Scholar

• 30

  ElhelalyNSElhawaryIMAlazizIAAAlsalamMIAElfishawyHMSherifMM. The Clinical Utility of Vascular Endothelial Growth Factor as Predictive Marker for Systemic Lupus Erythematosus Activity in Children and Adolescents. J Biol Sci (2009) 9:549–54. doi: 10.3923/jbs.2009.549.554

  • CrossRef
  • Google Scholar

• 31

  EdelbauerMKshirsagarSRiedlMBillingHTonshoffBHaffnerDet al. Soluble VEGF Receptor 1 Promotes Endothelial Injury in Children and Adolescents With Lupus Nephritis. Pediatr Nephrol (2012) 27:793–800. doi: 10.1007/s00467-011-2062-z

  • CrossRef
  • Google Scholar

• 32

  El-GazzarIIIbrahimSEEl-SawyWSFathiHMEissaAH. Assessment of Vascular Endothelial Growth Factor in Systemic Lupus Erythematosus Patients With Anti-Phospholipid Syndrome. Egyptian Rheumatol (2019) 41:41–5. doi: 10.1016/j.ejr.2018.03.005

  • CrossRef
  • Google Scholar

• 33

  GhazaliWSWIberahimRAshariNSM. Serum Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Disease Activity in Lupus Nephritis. Malays J Med Sci (2017) 24:62–72. doi: 10.21315/mjms2017.24.5.7

  • CrossRef
  • Google Scholar

• 34

  HeshmatNMEl-KerdanyTH. Serum Levels of Vascular Endothelial Growth Factor in Children and Adolescents With Systemic Lupus Erythematosus. Pediatr Allergy Immunol (2007) 18:346–53. doi: 10.1111/j.1399-3038.2006.00510.x

  • CrossRef
  • Google Scholar

• 35

  HrycekAJanowskaJCieslikP. Selected Angiogenic Cytokines in Systemic Lupus Erythematosus Patients. Autoimmunity (2009) 42:459–66. doi: 10.1080/08916930902960339

  • CrossRef
  • Google Scholar

• 36

  HrycekAPierzchałaWOsławska-DzierżęgaACieślikP. Selected Growth Factors and Diffusing Capacity of the Lung for Carbon Monoxide in Patients With Systemic Lupus Erythematosus. Rheumatol Int (2009) 30:175–9. doi: 10.1007/s00296-009-0930-7

  • CrossRef
  • Google Scholar

• 37

  IbrahimFFDrazHMAl SherbeniHH. Serum Levels of Vascular Endothelial Growth Factor and Hemoglobin Dielectric Properties in Patients With Systemic Lupus Erythematosus. J Med Sci (2008) 8:469–76. doi: 10.3923/jms.2008.469.476

  • CrossRef
  • Google Scholar

• 38

  KikuchiKKuboMKadonoTYazawaNIhnHTamakiK. Serum Concentrations of Vascular Endothelial Growth Factor in Collagen Diseases. Br J Dermatol (1998) 139:1049–51. doi: 10.1046/j.1365-2133.1998.02563.x

  • CrossRef
  • Google Scholar

• 39

  KocaSSAkbasFOzgenMYolbasSIlhanNGundogduBet al. Serum Galectin-3 Level in Systemic Sclerosis. Clin Rheumatol (2014) 33:215–20. doi: 10.1007/s10067-013-2346-8

  • CrossRef
  • Google Scholar

• 40

  Kuryliszyn-MoskalAKlimiukPASierakowskiSCiolkiewiczM. Vascular Endothelial Growth Factor in Systemic Lupus Erythematosus: Relationship to Disease Activity, Systemic Organ Manifestation, and Nailfold Capillaroscopic Abnormalities. Archivum Immunol Et Ther Experiment (2007) 55:179–85. doi: 10.1007/s00005-007-0017-7

  • CrossRef
  • Google Scholar

• 41

  LiuJWangXYangXYanQWangSHanW. Investigating the Role of Angiogenesis in Systemic Lupus Erythematosus. Lupus (2015) 24:621–7. doi: 10.1177/0961203314556293

  • CrossRef
  • Google Scholar

• 42

  Merayo-ChalicoJBarrera-VargasAJuarez-VegaGAlcocer-VarelaJArauzAGomez-MartinD. Differential Serum Cytokine Profile in Patients With Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome. Clin Exp Immunol (2018) 192:165–70. doi: 10.1111/cei.13095

  • CrossRef
  • Google Scholar

• 43

  NovikovAAleksandrovaEVerizhnikovaZPanafidinaTPopkovaTKarateevDet al. Cytokine Profiles in Systemic Lupus Erythematosus and Rheumatoid Arthritis. Ann Rheumatic Dis (2016) 75:907. doi: 10.1136/annrheumdis-2016-eular.3130

  • CrossRef
  • Google Scholar

• 44

  MoneibHASalemSAMAlyDGKhedrHTMWafaeyHAHassanHE. Assessment of Serum Vascular Endothelial Growth Factor and Nail Fold Capillaroscopy Changes in Systemic Lupus Erythematosus With and Without Cutaneous Manifestations. J Dermatol (2012) 39:52–7. doi: 10.1111/j.1346-8138.2011.01322.x

  • CrossRef
  • Google Scholar

• 45

  NavarroCCandia-ZúñigaLSilveiraLHRuizVGaxiolaMAvilaMCet al. Vascular Endothelial Growth Factor Plasma Levels in Patients With Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome. Lupus (2002) 11:21–4. doi: 10.1191/0961203302lu131oa

  • CrossRef
  • Google Scholar

• 46

  RobakEWierzbowskaAChmielaMKulczyckaLSysa-JedrejowskaARobakT. Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients With Systemic Lupus Erythomatosus. Mediators Inflamm (2006) 2006:17898. doi: 10.1155/mi/2006/17898

  • CrossRef
  • Google Scholar

• 47

  RobakESysa-JedrzejewskaARobakT. Vascular Endothelial Growth Factor and its Soluble Receptors VEGFR-1 and VEGFR-2 in the Serum of Patients With Systemic Lupus Erythematosus. Mediators Inflamm (2003) 12:293–8. doi: 10.1080/09629350310001619726

  • CrossRef
  • Google Scholar

• 48

  RobakEKulczycka-SiennickaLGerliczZKierstanMKorycka-WolowiecASysa-JedrzejowskaA. Correlations Between Concentrations of Interleukin (IL)-17A, IL-17B and IL-17F, and Endothelial Cells and Proangiogenic Cytokines in Systemic Lupus Erythematosus Patients. Eur Cytokine Netw (2013) 24:60–8. doi: 10.1684/ecn.2013.0330

  • CrossRef
  • Google Scholar

• 49

  RobakEWoźniackaASysa-JedrzejowskaAStepieńHRobakT. Circulating Angiogenesis Inhibitor Endostatin and Positive Endothelial Growth Regulators in Patients With Systemic Lupus Erythematosus. Lupus (2002) 11:348–55. doi: 10.1191/0961203302lu199oa

  • CrossRef
  • Google Scholar

• 50

  WillisRSmikleMDeCeulaerKRomay-PenabadZPapalardoEJajoriaPet al. Clinical Associations of Proinflammatory Cytokines, Oxidative Biomarkers and Vitamin D Levels in Systemic Lupus Erythematosus. Lupus (2017) 26:1517–27. doi: 10.1177/0961203317706557

  • CrossRef
  • Google Scholar

• 51

  ZhouLLuGYShenLWangLFWangMJ. Serum Levels of Three Angiogenic Factors in Systemic Lupus Erythematosus and Their Clinical Significance. BioMed Res Int (2014) 2014:627126. doi: 10.1155/2014/627126

  • CrossRef
  • Google Scholar

• 52

  ArdicogluOBozKKamanliAKavuncuVCanatanHOnalSet al. Levels of Vascular Endothelial Growth Factor in Patients With Rheumatoid Arthritis. Pain Clin (2004) 16:187–91. doi: 10.1163/156856904774134406

  • CrossRef
  • Google Scholar

• 53

  BottomleyMJWebbNJWatsonCJHoltLBukhariMDentonJet al. Placenta Growth Factor (PlGF) Induces Vascular Endothelial Growth Factor (VEGF) Secretion From Mononuclear Cells and is Co-Expressed With VEGF in Synovial Fluid. Clin Exp Immunol (2000) 119:182–8. doi: 10.1046/j.1365-2249.2000.01097.x

  • CrossRef
  • Google Scholar

• 54

  ChoMLJungYOMoonYMMinSYYoonCHLeeSHet al. Interleukin-18 Induces the Production of Vascular Endothelial Growth Factor (VEGF) in Rheumatoid Arthritis Synovial Fibroblasts. Via AP-1-Dependent Pathways Immunol Lett (2006) 103:159–66. doi: 10.1016/j.imlet.2005.10.020

  • CrossRef
  • Google Scholar

• 55

  DeveciKButunIDeveciH. Evaluation of Nitric Oxide and Angiogenic Factors in Rheumatoid Arthritis and Ankylosing Spondylitis Patients. FEBS J (2016) 283:244–5. doi: 10.1111/febs.13808

  • CrossRef
  • Google Scholar

• 56

  DrouartMSaasPBillotMCedozJPTiberghienPWendlingDet al. High Serum Vascular Endothelial Growth Factor Correlates With Disease Activity of Spondylarthropathies. Clin Exp Immunol (2003) 132:158–62. doi: 10.1046/j.1365-2249.2003.02101.x

  • CrossRef
  • Google Scholar

• 57

  do PradoADBisiMCPiovesanDMBredemeierMBatistaTSPetersenLet al. Ultrasound Power Doppler Synovitis is Associated With Plasma IL-6 in Established Rheumatoid Arthritis. Cytokine (2016) 83:27–32. doi: 10.1016/j.cyto.2016.03.014

  • CrossRef
  • Google Scholar

• 58

  GumusACoskunCEmreHOTemelMInalBBSevalHet al. Evaluation of Vascular Endothelial Growth Factor Levels in Rheumatoid Arthritis Patients, With and Without Joint Swelling; a Comparison With Erythrocyte Sedimentation Rate, C-reactive Protein, Rheumatoid Factor and Anti-Cyclic Citruillnated Protein. Turkish J Biochem-Turk Biyokim Dergisi (2018) 43:76–82. doi: 10.1515/tjb-2016-0308

  • CrossRef
  • Google Scholar

• 59

  HeardBJRosvoldJMFritzlerMJEl-GabalawyHWileyJPKrawetzRJ. A Computational Method to Differentiate Normal Individuals, Osteoarthritis and Rheumatoid Arthritis Patients Using Serum Biomarkers. J R Soc Interface (2014) 11:20140428. doi: 10.1098/rsif.2014.0428

  • CrossRef
  • Google Scholar

• 60

  HetlandMLChristensenIJLottenburgerTJohansenJSSvendsenMNHorslev-PetersenKet al. Circulating VEGF as a Biological Marker in Patients With Rheumatoid Arthritis? Preanalytical and Biological Variability in Healthy Persons and in Patients. Dis Markers (2008) 24:1–10. doi: 10.1155/2008/707864

  • CrossRef
  • Google Scholar

• 61

  HashimotoNIwasakiTKitanoMOgataAHamanoT. Levels of Vascular Endothelial Growth Factor and Hepatocyte Growth Factor in Sera of Patients With Rheumatic Diseases. Mod Rheumatol (2003) 13:129–34. doi: 10.3109/s10165-002-0211-8

  • CrossRef
  • Google Scholar

• 62

  KimHRParkMKChoMLYoonCHLeeSHParkSHet al. Macrophage Migration Inhibitory Factor Upregulates Angiogenic Factors and Correlates With Clinical Measures in Rheumatoid Arthritis. J Rheumatol (2007) 34(5):927–36.

  • Google Scholar

• 63

  Kuryliszyn-MoskalAKlimiukPASierakowskiSCiolkiewiczM. A Study on Vascular Endothelial Growth Factor and Endothelin-1 in Patients With Extra-Articular Involvement of Rheumatoid Arthritis. Clin Rheumatol (2006) 25:314–9. doi: 10.1007/s10067-005-0007-2

  • CrossRef
  • Google Scholar

• 64

  KuwanaMOkazakiYYasuokaHKawakamiYIkedaY. Defective Vasculogenesis in Systemic Sclerosis. Lancet (2004) 364:603–10. doi: 10.1016/s0140-6736(04)16853-0

  • CrossRef
  • Google Scholar

• 65

  MilmanNKarshJBoothRA. Correlation of a Multi-Cytokine Panel With Clinical Disease Activity in Patients With Rheumatoid Arthritis. Clin Biochem (2010) 43:1309–14. doi: 10.1016/j.clinbiochem.2010.07.012

  • CrossRef
  • Google Scholar

• 66

  OlszewskiWLPazdurJKubasiewiczEZaleskaMCookeCJMillerNE. Lymph Draining From Foot Joints in Rheumatoid Arthritis Provides Insight Into Local Cytokine and Chemokine Production and Transport to Lymph Nodes. Arthritis Rheumatol (2001) 44:541–9. doi: 10.1002/1529-0131(200103)44:3<541::Aid-anr102>3.0.Co;2-6

  • CrossRef
  • Google Scholar

• 67

  OranskiySPYeliseyevaLNTsanaevaAVZaytsevaNV. Body Composition and Serum Levels of Adiponectin, Vascular Endothelial Growth Factor, and Interleukin-6 in Patients With Rheumatoid Arthritis. Croatian Med J (2012) 53:350–6. doi: 10.3325/cmj.2012.53.350

  • CrossRef
  • Google Scholar

• 68

  OzgonenelLCetinETutunSTonbaklarPAralHGuvenenG. The Relation of Serum Vascular Endothelial Growth Factor Level With Disease Duration and Activity in Patients With Rheumatoid Arthritis. Clin Rheumatol (2010) 29:473–7. doi: 10.1007/s10067-009-1343-4

  • CrossRef
  • Google Scholar

• 69

  YoungHRChungCPOeserASolusJAsanumaYSokkaTet al. Inflammatory Mediators and Premature Coronary Atherosclerosis in Rheumatoid Arthritis. Arthritis Care Res (2009) 61:1580–5. doi: 10.1002/art.25009

  • CrossRef
  • Google Scholar

• 70

  Rodriguez-CarrioJAlperi-LopezMLopez-MejiasRLopezPBallina-GarciaFJAbalFet al. Antibodies to Paraoxonase 1 are Associated With Oxidant Status and Endothelial Activation in Rheumatoid Arthritis. Clin Sci (2016) 130:1889–99. doi: 10.1042/cs20160374

  • CrossRef
  • Google Scholar

• 71

  SmetsPDevauchelle-PensecVRouzairePOPereiraBAndreMSoubrierM. Vascular Endothelial Growth Factor Levels and Rheumatic Diseases of the Elderly. Arthritis Res Ther (2016) 18:283. doi: 10.1186/s13075-016-1184-x

  • CrossRef
  • Google Scholar

• 72

  StrunkJHeinemannENeeckGSchmidtKLLangeU. A New Approach to Studying Angiogenesis in Rheumatoid Arthritis by Means of Power Doppler Ultrasonography and Measurement of Serum Vascular Endothelial Growth Factor. Rheumatol (Oxford) (2004) 43:1480–3. doi: 10.1093/rheumatology/keh380

  • CrossRef
  • Google Scholar

• 73

  TsengJCKengHMYenLJWangLFHuRJLuLY. Analysis of Serum Vascular Endothelial Growth Factor and Angiogenesis Inhibitor Endostatin Concentrations in Patients With Different Arthritis. Int J Rheumatic Dis (2010) 13:79. doi: 10.1111/j.1756-185X.2010.01497.x

  • CrossRef
  • Google Scholar

• 74

  ZayedAAmerHNasarHIbrahiemAMottawieH. Some Biochemical Changes in Serum and Synovial Fluid of Patients With Rheumatoid Arthritis. J Med Sci (2007) 7:526–35. doi: 10.3923/jms.2007.526.535

  • CrossRef
  • Google Scholar

• 75

  AlekperovRAlexandrovaENovikovAAnanyevaL. Clinical Associations of Vascular Endothelial Growth Factor And its Receptor 2 Type in Systemic Sclerosis. Ann Rheumatic Dis (2018) 77:1531–. doi: 10.1136/annrheumdis-2018-eular.4064

  • CrossRef
  • Google Scholar

• 76

  AllanoreYBorderieDLemaréchalHEkindjianOGKahanA. Nifedipine Decreases sVCAM-1 Concentrations and Oxidative Stress in Systemic Sclerosis But Does Not Affect the Concentrations of Vascular Endothelial Growth Factor or its Soluble Receptor 1. Arthritis Res Ther (2004) 6:R309–14. doi: 10.1186/ar1183

  • CrossRef
  • Google Scholar

• 77

  AydogduEPamukONDonmezSPamukGE. Decreased interleukin-20 Level in Patients With Systemic Sclerosis: Are They Related With Angiogenesis? Clin Rheumatol (2013) 32:1599–603. doi: 10.1007/s10067-013-2317-0

  • CrossRef
  • Google Scholar

• 78

  BenyamineAMagalonJCointeSLacroixRArnaudLBardinNet al. Increased Serum Levels of Fractalkine and Mobilisation of CD34+CD45- Endothelial Progenitor Cells in Systemic Sclerosis. Arthritis Res Ther (2017) 19:60. doi: 10.1186/s13075-017-1271-7

  • CrossRef
  • Google Scholar

• 79

  BoselloSLCanestrariGCapacciADi GiorgioADe LucaGBocciMet al. Fmd, VEGF, and IL-6 in Vedoss Patients: The Precocity of Endothelial Dysfunction. Ann Rheumatic Dis (2014) 73. doi: 10.1136/annrheumdis-2014-eular.4446

  • CrossRef
  • Google Scholar

• 80

  BoselloSLDi GiorgioAFotiFDe LucaGBocciMParisiFet al. Decrease of Brachial Artery Endothelial-Dependent Flow-Mediated Dilation Characterizes Very Early Systemic Sclerosis (VEDOSS) Patients. Clin Exp Rheumatol (2014) 32:S23.

  • Google Scholar

• 81

  ChoraIRomanoEManettiMMazzottaCCostaRMachadoVet al. Evidence for a Derangement of the Microvascular System in Patients With a Very Early Diagnosis of Systemic Sclerosis. J Rheumatol (2017) 44:1190–7. doi: 10.3899/jrheum.160791

  • CrossRef
  • Google Scholar

• 82

  CossuMAndraccoRSantanielloAMarchiniMSeverinoACaronniMet al. Serum Levels of Vascular Dysfunction Markers Reflect Disease Severity and Stage in Systemic Sclerosis Patients. Rheumatology (2016) 55:1112–6. doi: 10.1093/rheumatology/kew017

  • CrossRef
  • Google Scholar

• 83

  De LauretisASestiniPPantelidisPHoylesRHansellDMGohNSLet al. Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. J Rheumatol (2013) 40:435–46. doi: 10.3899/jrheum.120725

  • CrossRef
  • Google Scholar

• 84

  Delle SedieARienteLMaggioriniLPratesiFTavoniAMiglioriniPet al. Potential Biomarkers in Patients With Systemic Sclerosis. Int J Rheum Dis (2018) 21:261–5. doi: 10.1111/1756-185x.13196

  • CrossRef
  • Google Scholar

• 85

  DistlerJHWStrapatsasTHuscherDDeesCAkhmetshinaAKienerHPet al. Dysbalance of Angiogenic and Angiostatic Mediators in Patients With Mixed Connective Tissue Disease. Ann Rheumatic Dis (2011) 70:1197–202. doi: 10.1136/ard.2010.140657

  • CrossRef
  • Google Scholar

• 86

  DistlerODel RossoAGiacomelliRCiprianiPConfortiMLGuiducciSet al. Angiogenic and Angiostatic Factors in Systemic Sclerosis: Increased Levels of Vascular Endothelial Growth Factor are a Feature of the Earliest Disease Stages and are Associated With the Absence of Fingertip Ulcers. Arthritis Res (2002) 4:R11. doi: 10.1186/ar596

  • CrossRef
  • Google Scholar

• 87

  DunneJVKeenKJVan EedenSF. Circulating Angiopoietin and Tie-2 Levels in Systemic Sclerosis. Rheumatol Int (2013) 33:475–84. doi: 10.1007/s00296-012-2378-4

  • CrossRef
  • Google Scholar

• 88

  Dziankowska-BartkowiakBWaszczykowskaEZalewskaASysa-JedrzejowskaA. Correlation of Endostatin and Tissue Inhibitor of Metalloproteinases 2 (TIMP2) Serum Levels With Cardiovascular Involvement in Systemic Sclerosis Patients. Mediators Inflamm (2005) 2005:144–9. doi: 10.1155/mi.2005.144

  • CrossRef
  • Google Scholar

• 89

  Dziankowska-BartkowiakBWaszczykowskaEDziankowska-ZaboroszczykEde Graft-JohnsonJEZalewskaAŁuczyńskaMet al. Decreased Ratio of Circulatory Vascular Endothelial Growth Factor to Endostatin in Patients With Systemic Sclerosis–Association With Pulmonary Involvement. Clin Exp Rheumatol (2006) 24(5):508–13.

  • Google Scholar

• 90

  FaroukHMHamzaSHEl BakrySAYoussefSSAlyIMMoustafaAAet al. Dysregulation of Angiogenic Homeostasis in Systemic Sclerosis. Int J Rheumatic Dis (2013) 16:448–54. doi: 10.1111/1756-185x.12130

  • CrossRef
  • Google Scholar

• 91

  Gkodkowska-MrowkaEGorskaECiurzynskiMStelmaszczyk-EmmelABieniasPIrzykKet al. Pro- and Antiangiogenic Markers in Patients With Pulmonary Complications of Systemic Scleroderma. Respir Physiol Neurobiol (2015) 209:69–75. doi: 10.1016/j.resp.2014.10.018

  • CrossRef
  • Google Scholar

• 92

  GiganteANavariniLMargiottaDBarbanoBAfeltraARosatoE. Female Sexual Dysfunction in Systemic Sclerosis: The Role of Endothelial Growth Factor and Endostatin. J Scleroderma Related Disord (2019) 4:71–6. doi: 10.1177/2397198318776593

  • CrossRef
  • Google Scholar

• 93

  HummersLKHallAWigleyFMSimonsM. Abnormalities in the Regulators of Angiogenesis in Patients With Scleroderma. J Rheumatol (2009) 36:576–82. doi: 10.3899/jrheum.080516

  • CrossRef
  • Google Scholar

• 94

  IbrahimSEMoradCSFaroukNLouisA. Platelet Indices as Markers of Inflammation in Systemic Sclerosis Patients: Relation to Vascular Endothelial Growth Factor and Flow Mediated Dilatation. Egyptian Rheumatol (2018) 40:239–42. doi: 10.1016/j.ejr.2017.12.001

  • CrossRef
  • Google Scholar

• 95

  KawashiriSNishinoAIgawaTTakataniAShimizuTUmedaMet al. Prediction of Organ Involvement in Systemic Sclerosis by Serum Biomarkers and Peripheral Endothelial Function. Clin Exp Rheumatol (2018) 36(4):S102–S8.

  • Google Scholar

• 96

  Kuryliszyn-MoskalAKlimiukPASierakowskiS. Soluble Adhesion Molecules (sVCAM-1, sE-selectin), Vascular Endothelial Growth Factor (VEGF) and Endothelin-1 in Patients With Systemic Sclerosis: Relationship to Organ Systemic Involvement. Clin Rheumatol (2005) 24:111–6. doi: 10.1007/s10067-004-0987-3

  • CrossRef
  • Google Scholar

• 97

  LvTTYangFFZhangKLvMHZhangYZhuP. The Risk of Circulating Angiogenic T Cells and Subsets in Patients With Systemic Sclerosis. Int Immunopharmacol (2020) 81:106282. doi: 10.1016/j.intimp.2020.106282

  • CrossRef
  • Google Scholar

• 98

  Michalska-JakubusMCutoloMSmithVKrasowskaD. Imbalanced Serum Levels of Ang1, Ang2 and VEGF in Systemic Sclerosis: Integrated Effects on Microvascular Reactivity. Microvascular Res (2019) 125:103881. doi: 10.1016/j.mvr.2019.103881

  • CrossRef
  • Google Scholar

• 99

  MinierTNagyZBalintZFarkasHRadicsJKumanovicsGet al. Construct Validity Evaluation of the European Scleroderma Study Group Activity Index, and Investigation of Possible New Disease Activity Markers in Systemic Sclerosis. Rheumatology (2010) 49:1133–45. doi: 10.1093/rheumatology/keq022

  • CrossRef
  • Google Scholar

• 100

  MorgielEWilandGPiesiakPBogutBWilandP. VEGF Serum Levels as an Indicator of a Visceral Involvement in SSc. Rheumatology (2012) 51:ii75. doi: 10.1093/rheumatology/ker475

  • CrossRef
  • Google Scholar

• 101

  PapaioannouAIZakynthinosEKostikasKKiropoulosTKoutsokeraAZiogasAet al. Serum VEGF Levels are Related to the Presence of Pulmonary Arterial Hypertension in Systemic Sclerosis. BMC Pulm Med (2009) 9:18. doi: 10.1186/1471-2466-9-18

  • CrossRef
  • Google Scholar

• 102

  ReiseterSMolbergOGunnarssonRLundMBAalokkenTMAukrustPet al. Associations Between Circulating Endostatin Levels and Vascular Organ Damage in Systemic Sclerosis and Mixed Connective Tissue Disease: An Observational Study. Arthritis Res Ther (2015) 17(1):231. doi: 10.1186/s13075-015-0756-5

  • CrossRef
  • Google Scholar

• 103

  SatoSHasegawaMTakeharaK. Serum Levels of Interleukin-6 and interleukin-10 Correlate With Total Skin Thickness Score in Patients With Systemic Sclerosis. J Dermatol Sci (2001) 27:140–6. doi: 10.1016/s0923-1811(01)00128-1

  • CrossRef
  • Google Scholar

• 104

  RiccieriVStefanantoniKVasileMMacriVSciarraIIannaceNet al. Abnormal Plasma Levels of Different Angiogenic Molecules are Associated With Different Clinical Manifestations in Patients With Systemic Sclerosis. Clin Exp Rheumatol (2011) 29(2):S46–52.

  • Google Scholar

• 105

  SaranyaCRameshRBhuvaneshMBalajiCBalameenaSRajeswariS. Serum Vascular Endothelial Growth Factor Levels as a Marker of Skin Thickening, Digital Ischemia, and Interstitial Lung Disease in Systemic Sclerosis. Indian J Rheumatol (2018) 13:182–5. doi: 10.4103/injr.injr_132_17

  • CrossRef
  • Google Scholar

• 106

  ShenavandehSTarakemehTSarvestaniEKNazariniaMA. Serum Vascular Endothelial Growth Factor (VEGF), Soluble VEGF Receptor-1 (sVEGFR-1) and sVEGFR-2 in Systemic Sclerosis Patients: Relation to Clinical Manifestations and Capillaroscopy Findings. Egyptian Rheumatol (2017) 39:19–24. doi: 10.1016/j.ejr.2016.03.004

  • CrossRef
  • Google Scholar

• 107

  SolanillaAVilleneuveJAugustePHuguesMAlioumALepreuxSet al. The Transport of High Amounts of Vascular Endothelial Growth Factor by Blood Platelets Underlines Their Potential Contribution in Systemic Sclerosis Angiogenesis. Rheumatology (2009) 48:1036–44. doi: 10.1093/rheumatology/kep154

  • CrossRef
  • Google Scholar

• 108

  YalcinkayaYAdin-CinarSArtim-EsenBKamaliSPehlivanOOcalLet al. Capillaroscopic Findings and Vascular Biomarkers in Systemic Sclerosis: Association of Low CD40L Levels With Late Scleroderma Pattern. Microvascular Res (2016) 108:17–21. doi: 10.1016/j.mvr.2016.07.002

  • CrossRef
  • Google Scholar

• 109

  WaszczykowskaAGosRWaszczykowskaEDziankowska-BartkowiakBPodgorskiMJurowskiP. The Role of Angiogenesis Factors in the Formation of Vascular Changes in Scleroderma by Assessment of the Concentrations of VEGF and sVEGFR2 in Blood Serum and Tear Fluid. Mediators Inflammation (2020) 2020. doi: 10.1155/2020/7649480

  • CrossRef
  • Google Scholar

• 110

  WipffJAvouacJBorderieDZerkakDLemarechalHKahanAet al. Disturbed Angiogenesis in Systemic Sclerosis: High Levels of Soluble Endoglin. Rheumatology (2008) 47:972–5. doi: 10.1093/rheumatology/ken100

  • CrossRef
  • Google Scholar

• 111

  AricaDAAksanBOremAAltinkaynakBAYayliSSonmezM. High Levels of Endothelial Progenitor Cells and Circulating Endothelial Cells in Patients With Behcet’s Disease and Their Relationship to Disease Activity. Anais Brasileiros Dermatol (2019) 94:320–6. doi: 10.1590/abd1806-4841.20198169

  • CrossRef
  • Google Scholar

• 112

  CekmenMEverekliogluCErHInalözHSDoganaySTürközYet al. Vascular Endothelial Growth Factor Levels are Increased and Associated With Disease Activity in Patients With Behçet’s Syndrome. Int J Dermatol (2003) 42:870–5. doi: 10.1046/j.1365-4362.2003.01688.x

  • CrossRef
  • Google Scholar

• 113

  EldinABIbrahimA. Assessment of the Relationship Between Vascular Endothelial Growth Factor and Cardiovascular Involvement in Egyptian Patients With Behçet’s Disease. Egyptian Rheumatol (2014) 36:131–7. doi: 10.1016/j.ejr.2013.12.006

  • CrossRef
  • Google Scholar

• 114

  ErdemFGündoğduMKikiIAli SariRKiziltunçA. Vascular Endothelial and Basic Fibroblast Growth Factor Serum Levels in Patients With Behçet’s Disease. Rheumatol Int (2005) 25:599–603. doi: 10.1007/s00296-004-0484-7

  • CrossRef
  • Google Scholar

• 115

  GanebSSSabryHHEl-AssalMMKamalHMFayedAAEl-ShazlyIM. Vascular Endothelial Growth Factor and Subclinical Atherosclerosis by Carotid Ultrasonography in Egyptian Patients With Behçet’s Disease. Egyptian Rheumatol (2013) 35:87–94. doi: 10.1016/j.ejr.2012.12.001

  • CrossRef
  • Google Scholar

• 116

  GheitaTASakrBRRabeaREAbd ElHamidSM. Value of Hematological Indices Versus VEGF as Biomarkers of Activity in Behcet’s Disease. Clin Rheumatol (2019) 38:2201–10. doi: 10.1007/s10067-019-04513-5

  • CrossRef
  • Google Scholar

• 117

  IbrahimSEElshishtawyHFHelmysamyAGalalZA. Role of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Behçet’s Disease. Indian J Rheumatol (2011) 6:168–72. doi: 10.1016/S0973-3698(11)60202-1

  • CrossRef
  • Google Scholar

• 118

  KulAAteşOAlkan MelikoğluMUğurMÖztürkNErkayhanGet al. Endocan Measurement for Active Behçet Disease. Arch Rheumatol (2017) 32:197–202. doi: 10.5606/ArchRheumatol.2017.6072

  • CrossRef
  • Google Scholar

• 119

  OzdamarYBerkerNBaharGSoykanEBicerTOzkanSSet al. Inflammatory Mediators and Posterior Segment Involvement in Ocular Behcet Disease. Eur J Ophthalmol (2009) 19:998–1003. doi: 10.1177/112067210901900616

  • CrossRef
  • Google Scholar

• 120

  OzturkMAUnverdiSOktarSOBukanNGulbaharOUretenKet al. Vascular Endothelial Growth Factor and Carotid Intima-Media Thickness in Patients With Behcet’s Disease. Clin Rheumatol (2008) 27:961–6. doi: 10.1007/s10067-007-0825-5

  • CrossRef
  • Google Scholar

• 121

  SertogluEOmmaAYucelCColakSSandikciSCOzgurtasT. The Relationship of Serum VEGF and sVEGFR-1 Levels With Vascular Involvement in Patients With Behcet’s Disease. Scandinavian J Clin Lab Invest (2018) 78:443–9. doi: 10.1080/00365513.2018.1488179

  • CrossRef
  • Google Scholar

• 122

  ShakerOAy El-DeenMAEl HadidiHGraceBDEl SherifHAbdel HalimA. The Role of Heat Shock Protein 60, Vascular Endothelial Growth Factor and Antiphospholipid Antibodies in Behçet Disease. Br J Dermatol (2007) 156:32–7. doi: 10.1111/j.1365-2133.2006.07536.x

  • CrossRef
  • Google Scholar

• 123

  YalcindagAGedik-OguzYYalcindagFN. The Relationship Between Serum Levels of Angiogenin, Bfgf, VEGF, and Ocular Involvement in Patients With Behcet’s Disease. Graefes Arch Clin Exp Ophthalmol (2013) 251:1807–12. doi: 10.1007/s00417-013-2322-7

  • CrossRef
  • Google Scholar

• 124

  BreunisWBDavilaSShimizuCOharasekiTTakahashiKvan HoudtMet al. Disruption of Vascular Homeostasis in Patients With Kawasaki Disease: Involvement of Vascular Endothelial Growth Factor and Angiopoietins. Arthritis Rheumatism (2012) 64:306–15. doi: 10.1002/art.33316

  • CrossRef
  • Google Scholar

• 125

  HamamichiYIchidaFYuXHironoKIUeseKIHashimotoIet al. Neutrophils and Mononuclear Cells Express Vascular Endothelial Growth Factor in Acute Kawasaki Disease: its Possible Role in Progression of Coronary Artery Lesions. Pediatr Res (2001) 49:74–80. doi: 10.1203/00006450-200101000-00017

  • CrossRef
  • Google Scholar

• 126

  MaenoNTakeiSMasudaKAkaikeHMatsuoKKitajimaIet al. Increased Serum Levels of Vascular Endothelial Growth Factor in Kawasaki Disease. Pediatr Res (1998) 44:596–9. doi: 10.1203/00006450-199810000-00021

  • CrossRef
  • Google Scholar

• 127

  OhnoTYugeTKariyazonoHIgarashiHJoh-oKKinugawaNet al. Serum Hepatocyte Growth Factor Combined With Vascular Endothelial Growth Factor as a Predictive Indicator for the Occurrence of Coronary Artery Lesions in Kawasaki Disease. Eur J Pediatr (2002) 161:105–11. doi: 10.1007/s00431-001-0860-1

  • CrossRef
  • Google Scholar

• 128

  SuYFengSQLuoLLiuRXYiQJ. Association Between IL-35 and Coronary Arterial Lesions in Children With Kawasaki Disease. Clin Exp Med (2019) 19:87–92. doi: 10.1007/s10238-018-0513-6

  • CrossRef
  • Google Scholar

• 129

  UenoKNomuraYHashiguchiTMasudaKMoritaYHazekiDet al. Platelet Vascular Endothelial Growth Factor is a Useful Predictor for Prognosis in Kawasaki Syndrome. Br J Haematol (2010) 148:285–92. doi: 10.1111/j.1365-2141.2009.07922.x

  • CrossRef
  • Google Scholar

• 130

  ZengHWeiR. Relationship Between Vascular Endothelial Growth Factor and Vascular Injury of Children Kawasaki Disease. Int J Rheumatic Dis (2016) 19:153. doi: 10.1111/1756-185X.12962

  • CrossRef
  • Google Scholar

• 131

  AkarSSolmazDBulbulHUsluSKozaciDKaracaNet al. Serum Level of the Vascular Endothelial Growth Factor is Elevated in Ankylosing Spondylitis and Osteocalcin may be Related With Osteoproliferation. Int J Rheumatic Dis (2016) 19:239. doi: 10.1111/1756-185X.12962

  • CrossRef
  • Google Scholar

• 132

  GoldbergerCDulakJDuftnerCWeidingerFFalkenbachASchirmerM. Vascular Endothelial Growth Factor (VEGF) in Ankylosing Spondylitis–a Pilot Study. Wien Med Wochenschr (2002) 152:223–5. doi: 10.1046/j.1563-258x.2002.01118.x

  • CrossRef
  • Google Scholar

• 133

  LinTTLuJQiCYYuanLLiXLXiaLPet al. Elevated Serum Level of IL-27 and VEGF in Patients With Ankylosing Spondylitis and Associate With Disease Activity. Clin Exp Med (2015) 15:227–31. doi: 10.1007/s10238-014-0281-x

  • CrossRef
  • Google Scholar

• 134

  Przepiera-BedzakHFischerKBrzoskoM. EGF, Basic FGF, and Acidic FGF Levels and Their Association With Disease Activity and Extra-Articular Symptoms in Ankylosing Spondylitis. Polskie Archiwum Medycyny Wewnetrznej-Polish Arch Internal Med (2016) 126:290–2. doi: 10.20452/pamw.3341

  • CrossRef
  • Google Scholar

• 135

  Przepiera-BedzakHFischerKBrzoskoM. Serum IL-6 and IL-23 Levels and Their Correlation With Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Mediators Inflammation (2015) 2015:785705. doi: 10.1155/2015/785705

  • CrossRef
  • Google Scholar

• 136

  Przepiera-BedzakHFischerKBrzoskoM. Serum Interleukin-18, Fetuin-a, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Int J Mol Sci (2016) 17:1255. doi: 10.3390/ijms17081255

  • CrossRef
  • Google Scholar

• 137

  SakellariouGTIliopoulosAKonstaMKenanidisEPotoupnisMTsiridisEet al. Serum Levels of Dkk-1, Sclerostin and VEGF in Patients With Ankylosing Spondylitis and Their Association With Smoking, and Clinical, Inflammatory and Radiographic Parameters. Joint Bone Spine (2017) 84:309–15. doi: 10.1016/j.jbspin.2016.05.008

  • CrossRef
  • Google Scholar

• 138

  SolmazDBulbulHUsluSKozaciLDKaracaNAkarS. Serum Level of The Vascular Endothelial Growth Factor is Elevated in Ankylosing Spondylitis And Osteocalcin May be Related Wth Osteoproliferation. Ann Rheumatic Dis (2015) 74:943–. doi: 10.1136/annrheumdis-2015-eular.4931

  • CrossRef
  • Google Scholar

• 139

  SolmazDUsluSKozaciDKaracaNBulbulHTarhanEFet al. Evaluation of Periostin and Factors Associated With New Bone Formation in Ankylosing Spondylitis: Periostin may be Associated With the Wnt Pathway. Int J Rheumatic Dis (2018) 21:502–9. doi: 10.1111/1756-185x.13186

  • CrossRef
  • Google Scholar

• 140

  TorresLKlingbergENurkkalaMCarlstenHForsblad-d’EliaH. Hepatocyte Growth Factor is a Potential Biomarker for Osteoproliferation and Osteoporosis in Ankylosing Spondylitis. Osteoporosis Int (2019) 30:441–9. doi: 10.1007/s00198-018-4721-4

  • CrossRef
  • Google Scholar

• 141

  AksoyEKCetinkayaHSavasBEnsariATorgutalpvMEfeC. Vascular Endothelial Growth Factor, Endostatin Levels and Clinical Features Among Patients With Ulcerative Colitis and Irritable Bowel Syndrome and Among Healthy Controls: A Cross-Sectional Analytical Study. Sao Paulo Med J (2018) 136:543–50. doi: 10.1590/1516-3180.2018.0274161118

  • CrossRef
  • Google Scholar

• 142

  AlgabaALinaresPMEncarnacion Fernandez-ContrerasMFiguerolaACalvetXGuerraIet al. The Effects of Infliximab or Adalimumab on Vascular Endothelial Growth Factor and Angiopoietin 1 Angiogenic Factor Levels in Inflammatory Bowel Disease: Serial Observations in 37 Patients. Inflammatory Bowel Dis (2014) 20:695–702. doi: 10.1097/mib.0000000000000004

  • CrossRef
  • Google Scholar

• 143

  Di SabatinoACiccocioppoRArmelliniEMoreraRRicevutiLCazzolaPet al. Serum bFGF and VEGF Correlate Respectively With Bowel Wall Thickness and Intramural Blood Flow in Crohn’s Disease. Inflammation Bowel Dis (2004) 10:573–7. doi: 10.1097/00054725-200409000-00011

  • CrossRef
  • Google Scholar

• 144

  Dueñas PousaIMaté JiménezJSalcedo MoraXAbreuMTMoreno OteroRGisbertJP. Analysis of Soluble Angiogenic Factors in Crohn’s Disease: A Preliminary Study. Gastroenterol Hepatol (2007) 30:518–24. doi: 10.1157/13111682

  • CrossRef
  • Google Scholar

• 145

  FerranteMPierikMHenckaertsLJoossensMClaesKVan SchuerbeekNet al. The Role of Vascular Endothelial Growth Factor (VEGF) in Inflammatory Bowel Disease. Inflammation Bowel Dis (2006) 12:870–8. doi: 10.1097/01.mib.0000235095.01608.10

  • CrossRef
  • Google Scholar

• 146

  GrigaTGutzeitASommerkampCMayB. Increased Production of Vascular Endothelial Growth Factor by Peripheral Blood Mononuclear Cells in Patients With Inflammatory Bowel Disease. Eur J Gastroenterol Hepatol (1999) 11:175–9. doi: 10.1097/00042737-199902000-00019

  • CrossRef
  • Google Scholar

• 147

  GrigaTTrommASprangerJMayB. Increased Serum Levels of Vascular Endothelial Growth Factor in Patients With Inflammatory Bowel Disease. Scand J Gastroenterol (1998) 33:504–8. doi: 10.1080/00365529850172070

  • CrossRef
  • Google Scholar

• 148

  KanazawaSTsunodaTOnumaEMajimaTKagiyamaMKikuchiK. VEGF. basic-FGF, and TGF-beta in Crohn’s Disease and Ulcerative Colitis: A Novel Mechanism of Chronic Intestinal Inflammation. Am J Gastroenterol (2001) 96:822–8. doi: 10.1111/j.1572-0241.2001.03527.x

  • CrossRef
  • Google Scholar

• 149

  KapsoritakisASfiridakiAMaltezosESimopoulosKGiatromanolakiASivridisEet al. Vascular Endothelial Growth Factor in Inflammatory Bowel Disease. Int J Colorectal Dis (2003) 18:418–22. doi: 10.1007/s00384-003-0495-y

  • CrossRef
  • Google Scholar

• 150

  KleinerGZaninVMonastaLCrovellaSCarusoLMilaniDet al. Pediatric Patients With Inflammatory Bowel Disease Exhibit Increased Serum Levels of Proinflammatory Cytokines and Chemokines, But Decreased Circulating Levels of Macrophage Inhibitory Protein-1β, Interleukin-2 and Interleukin-17. Exp Ther Med (2015) 9:2047–52. doi: 10.3892/etm.2015.2370

  • CrossRef
  • Google Scholar

• 151

  MagroFAraujoFPereiraPMeirelesEDiniz-RibeiroMVelosomFT. Soluble Selectins, sICAM, sVCAM, and Angiogenic Proteins in Different Activity Groups of Patients With Inflammatory Bowel Disease. Dig Dis Sci (2004) 49:1265–74. doi: 10.1023/b:ddas.0000037822.55717.31

  • CrossRef
  • Google Scholar

• 152

  PousaIDAlgabaALinaresPMSanz-CamenoPMateJMoreno-OteroRet al. Corticosteroids Modulate Angiogenic Soluble Factors in Ulcerative Colitis Patients. Digestive Dis Sci (2011) 56:871–9. doi: 10.1007/s10620-010-1327-x

  • CrossRef
  • Google Scholar

• 153

  PousaIDMateJSalcedo-MoraXAbreuMTMoreno-OteroRGisbertJP. Role of Vascular Endothelial Growth Factor and Angiopoietin Systems in Serum of Crohn’s Disease Patients. Inflammatory Bowel Dis (2008) 14:61–7. doi: 10.1002/ibd.20269

  • CrossRef
  • Google Scholar

• 154

  Schurer-MalyCCFriedMMalyFEBinekJFrenzerA. Vascular Endothelial Growth Factor in Serum of Patients With Inflammatory Bowel Disease [1]. Scandinavian J Gastroenterol (1997) 32:959–60. doi: 10.3109/00365529709011209

  • CrossRef
  • Google Scholar

• 155

  deZoetenEFBattistaKDColsonSBLovellMAKesslerBEIsfortRWet al. Markers of Hypoxia Correlate With Histologic and Endoscopic Severity of Colitis in Inflammatory Bowel Disease. Hypoxia (Auckl) (2020) 8:1–12. doi: 10.2147/hp.S219049

  • CrossRef
  • Google Scholar

• 156

  Wiercinska-DrapaloAJaroszewiczJParfieniukALapinskiTWRogalskaMProkopowiczD. Pigment Epithelium-Derived Factor in Ulcerative Colitis: Possible Relationship With Disease Activity. Regul Peptides (2007) 140:1–4. doi: 10.1016/j.regpep.2006.11.006

  • CrossRef
  • Google Scholar

• 157

  AkmanADicleOYilmazFCoskunMYilmazE. Discrepant Levels of Vascular Endothelial Growth Factor in Psoriasis Patients Treated With PUVA, Re-PUVA and Narrow-Band UVB. Photodermatol Photoimmunol Photomed (2008) 24:123–7. doi: 10.1111/j.1600-0781.2008.00349.x

  • CrossRef
  • Google Scholar

• 158

  AndersonKSPeterssonSWongJShubbarELokkoNNCarlstromMet al. Elevation of Serum Epidermal Growth Factor and Interleukin 1 Receptor Antagonist in Active Psoriasis Vulgaris. Br J Dermatol (2010) 163:1085–9. doi: 10.1111/j.1365-2133.2010.09990.x

  • CrossRef
  • Google Scholar

• 159

  Batycka-BaranAPaprockaMBaranWSzepietowskiJC. Decreased Number of Circulating Endothelial Progenitor Cells (CD133+/KDR+) in Patients With Psoriatic Arthritis. Acta Dermato-Venereol (2016) 96:754–7. doi: 10.2340/00015555-2353

  • CrossRef
  • Google Scholar

• 160

  Batycka-BaranAPaprockaMKrawczenkoAKantorADusDSzepietowskiJC. Reduced Number of Circulating Endothelial Progenitor Cells (CD133+/KDR+) in Patients With Plaque Psoriasis. Dermatology (2012) 225:88–92. doi: 10.1159/000341534

  • CrossRef
  • Google Scholar

• 161

  CapkinAADemirSMenteseABulutCAyarA. Can Signal peptide-CUB-EGF Domain-Containing Protein (SCUBE) Levels be a Marker of Angiogenesis in Patients With Psoriasis? Arch Dermatol Res (2017) 309:203–7. doi: 10.1007/s00403-017-1722-7

  • CrossRef
  • Google Scholar

• 162

  BhushanMMcLaughlinBWeissJBGriffithsCE. Levels of Endothelial Cell Stimulating Angiogenesis Factor and Vascular Endothelial Growth Factor are Elevated in Psoriasis. Br J Dermatol (1999) 141:1054–60. doi: 10.1046/j.1365-2133.1999.03205.x

  • CrossRef
  • Google Scholar

• 163

  CreamerDAllenMJaggarRStevensRBicknellRBarkerJ. Mediation of Systemic Vascular Hyperpermeability in Severe Psoriasis by Circulating Vascular Endothelial Growth Factor. Arch Dermatol (2002) 138:791–6. doi: 10.1001/archderm.138.6.791

  • CrossRef
  • Google Scholar

• 164

  FlisiakIZaniewskiPRogalskaMMysliwiecHJaroszewiczJChodynickaB. Effect of Psoriasis Activity on VEGF and its Soluble Receptors Concentrations in Serum and Plaque Scales. Cytokine (2010) 52:225–9. doi: 10.1016/j.cyto.2010.09.012

  • CrossRef
  • Google Scholar

• 165

  FinkAMCauzaEHassfeldWDunkyABayerPMJureckaWet al. Vascular Endothelial Growth Factor in Patients With Psoriatic Arthritis. Clin Exp Rheumatol (2007) 25:305–8.

  • Google Scholar

• 166

  KaurSZilmerKLepingVZilmerM. Comparative Study of Systemic Inflammatory Responses in Psoriasis Vulgaris and Mild to Moderate Allergic Contact Dermatitis. Dermatology (2012) 225:54–61. doi: 10.1159/000339866

  • CrossRef
  • Google Scholar

• 167

  MekiARAl-ShobailiH. Serum Vascular Endothelial Growth Factor, Transforming Growth Factor β1, and Nitric Oxide Levels in Patients With Psoriasis Vulgaris: Their Correlation to Disease Severity. J Clin Lab Anal (2014) 28:496–501. doi: 10.1002/jcla.21717

  • CrossRef
  • Google Scholar

• 168

  MiddeHSPriyadarssiniMRajappaMMunisamyMRajPSMSinghSet al. Interleukin-9 Serves as a Key Link Between Systemic Inflammation and Angiogenesis in Psoriasis. Clin Exp Dermatol. (2021) 46(1):50–7. doi: 10.1111/ced.14335

  • CrossRef
  • Google Scholar

• 169

  NielsenHJChristensenIJSvendsenMNHansenUWertherKBrünnerNet al. Elevated Plasma Levels of Vascular Endothelial Growth Factor and Plasminogen Activator Inhibitor-1 Decrease During Improvement of Psoriasis. Inflammation Res (2002) 51:563–7. doi: 10.1007/pl00012428

  • CrossRef
  • Google Scholar

• 170

  NofalAAl-MakhzangyIAttwaENassarAAbdalmoatiA. Vascular Endothelial Growth Factor in Psoriasis: An Indicator of Disease Severity and Control. J Eur Acad Dermatol Venereol (2009) 23:803–6. doi: 10.1111/j.1468-3083.2009.03181.x

  • CrossRef
  • Google Scholar

• 171

  Przepiera-BedzakHFischerKBrzoskoM. Serum Levels of Angiogenic Cytokines in Psoriatic Arthritis and SAPHO Syndrome. Polskie Archiwum Medycyny Wewnetrznej-Polish Arch Internal Med (2013) 123:297–302. doi: 10.20452/pamw.1772

  • CrossRef
  • Google Scholar

• 172

  Shahidi-DadrasMHaghighatkhahHRAbdollahimajdFYounespourSKiaMPZargariO. Correlation Between Vascular Endothelial Growth Factor and Subclinical Atherosclerosis in Patients With Psoriasis. Int J Dermatol (2016) 55:52–9. doi: 10.1111/ijd.12842

  • CrossRef
  • Google Scholar

• 173

  Shahidi-DadrasMAbdollahimajdFYounespourSNikvarM. Serum Vascular Endothelial Growth Factor in Iranian Patients With Moderate-Severe Psoriasis Before and After Treatment: A Pasi-75 Response as a Practical Treatment Goal. Iranian J Dermatol (2016) 19:119–24.

  • Google Scholar

• 174

  TakahashiHTsujiHHashimotoYIshida-YamamotoAIizukaH. Serum Cytokines and Growth Factor Levels in Japanese Patients With Psoriasis. Clin Exp Dermatol (2010) 35:645–9. doi: 10.1111/j.1365-2230.2009.03704.x

  • CrossRef
  • Google Scholar

• 175

  ZhengYZChenCFJiaLYYuTGSunJWangXY. Correlation Between microRNA-143 in Peripheral Blood Mononuclear Cells and Disease Severity in Patients With Psoriasis Vulgaris. Oncotarget (2017) 8:51288–95. doi: 10.18632/oncotarget.17260

  • CrossRef
  • Google Scholar

• 176

  Figueroa-VegaNSanz-CamenoPMoreno-OteroRSanchez-MadridFGonzalez-AmaroRMarazuelaM. Serum Levels of Angiogenic Molecules in Autoimmune Thyroid Diseases and Their Correlation With Laboratory and Clinical Features. J Clin Endocrinol Metab (2009) 94:1145–53. doi: 10.1210/jc.2008-1571

  • CrossRef
  • Google Scholar

• 177

  IitakaMMiuraSYamanakaKKawasakiSKitahamaSKawakamiYet al. Increased Serum Vascular Endothelial Growth Factor Levels and Intrathyroidal Vascular Area in Patients With Graves’ Disease and Hashimoto’s Thyroiditis. J Clin Endocrinol Metab (1998) 83:3908–12. doi: 10.1210/jcem.83.11.5281

  • CrossRef
  • Google Scholar

• 178

  KajdaniukDMarekBNiedziolka-ZielonkaDFoltynWNowakMSieminskaLet al. Transforming Growth Factor Beta 1 (TGF Beta 1) and Vascular Endothelial Growth Factor (VEGF) in the Blood of Healthy People and Patients With Graves’ Orbitopathy - a New Mechanism of Glucocorticoids Action? Endokrynol Polska (2014) 65:348–56. doi: 10.5603/ep.2014.0048

  • CrossRef
  • Google Scholar

• 179

  RancierMZaaberIStathopoulouMGChatelinJSalehAMarmouchHet al. Pro- and Anti-Angiogenic VEGF mRNAs in Autoimmune Thyroid Diseases. Autoimmunity (2016) 49:366–72. doi: 10.1080/08916934.2016.1199019

  • CrossRef
  • Google Scholar

• 180

  YeXLiuJWangYBinLWangJ. Increased Serum VEGF and b-FGF in Graves’ Ophthalmopathy. Graefe’s Arch Clin Exp Ophthalmol (2014) 252:1639–44. doi: 10.1007/s00417-014-2662-y

  • CrossRef
  • Google Scholar

• 181

  BreunisWBBiezeveldMHGeisslerJOttenkampJKuipersIMLamJet al. Vascular Endothelial Growth Factor Gene Haplotypes in Kawasaki Disease. Arthritis Rheumatol (2006) 54:1588–94. doi: 10.1002/art.21811

  • CrossRef
  • Google Scholar

• 182

  LeungDWCachianesGKuangWJGoeddelDVFerraraN. Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen. Science (1989) 246:1306–9. doi: 10.1126/science.2479986

  • CrossRef
  • Google Scholar

• 183

  DanveAO’DellJ. The Ongoing Quest for Biomarkers in Ankylosing Spondylitis. Int J Rheum Dis (2015) 18:826–34. doi: 10.1111/1756-185x.12779

  • CrossRef
  • Google Scholar

• 184

  HuangSMLiaoWTLinCFSunHSChowNH. Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients With Euthyroid Graves’ Disease. World J Surgery (2016) 40:505–9. doi: 10.1007/s00268-015-3298-8

  • CrossRef
  • Google Scholar

• 185

  BerrahmouneHLamontJVHerbethBFitzGeraldPSVisvikis-SiestS. Biological Determinants of and Reference Values for Plasma interleukin-8, Monocyte Chemoattractant protein-1, Epidermal Growth Factor, and Vascular Endothelial Growth Factor: Results From the STANISLAS Cohort. Clin Chem (2006) 52:504–10. doi: 10.1373/clinchem.2005.055798

  • CrossRef
  • Google Scholar